Psilocybin Therapy: What It Is, How It Works, and Where It’s Available

The woman in the Hopkins study had been diagnosed with terminal cancer six months earlier. She’d tried therapy. She’d tried antidepressants. She’d tried meditation, journaling, support groups—the full toolkit that modern medicine offers someone staring at their own death. The existential dread hadn’t moved. It sat on her chest like a physical weight, coloring every interaction with her children, her husband, the doctors who kept adjusting her medication and asking her to rate her anxiety on a scale of one to ten.

Then she put on eyeshades, lay down on a couch in a room designed to look nothing like a hospital, and spent six hours listening to music while two therapists sat quietly nearby. She’d taken a capsule containing 30 milligrams of synthetic psilocybin per 70 kilograms of body weight. Somewhere around hour two, she later reported, the fear didn’t diminish—it dissolved. Not gradually. Completely. She described feeling held by something she couldn’t name. She described understanding, with a certainty she’d never felt before, that her death was part of something larger and that she was safe inside it.

Six months later, her anxiety scores were still in the normal range. Not because the cancer was gone. It wasn’t. Because the relationship between her and the cancer had fundamentally changed.

That experience didn’t happen by accident. It happened inside a meticulously designed therapeutic protocol that took months to develop and years to validate. Psilocybin therapy isn’t “take mushrooms and hope for the best.” It’s one of the most structured, intentional applications of a psychoactive compound in the history of medicine. And the gap between what it actually is and what most people imagine it to be is worth closing, because that gap is where most of the confusion, the hype, and the legitimate risk all live.

What Psilocybin Therapy Actually Is

Psilocybin therapy is a structured clinical protocol in which a controlled dose of psilocybin is administered in a supervised therapeutic setting, embedded within a multi-session framework of psychological preparation and integration. The psilocybin session is the center of the process, but it’s not the whole process. Calling it “psilocybin therapy” is slightly misleading in the same way that calling surgery “cutting” is misleading—the cut matters, but the imaging, the planning, the anesthesia, and the recovery are what make it medicine instead of violence.

The standard protocol, as developed at Johns Hopkins University and adapted across most major research programs, follows a consistent structure:

1. Screening. Before anything else, a thorough psychiatric and medical evaluation. This isn’t a formality. It determines whether the candidate is safe to proceed. The screening excludes people with psychotic disorders, bipolar I disorder, certain cardiac conditions, and those on contraindicated medications (particularly lithium and MAOIs). Family history of psychotic disorders is also a disqualifier. This is one of the sharpest differences between clinical psilocybin therapy and unsupervised use—the screening catches the people for whom psilocybin carries genuine risk.

2. Preparation sessions. Typically two to three meetings with the therapists who will be present during the dosing session. These sessions establish trust, discuss the participant’s history and intentions, set expectations for the experience, and teach strategies for navigating difficult psychological material. The therapists don’t tell the participant what will happen—they can’t, because psilocybin experiences are radically individual. What they do is build a container: a relationship solid enough to hold whatever emerges.

The preparation phase is where the therapeutic alliance forms. Research on psychedelic therapy consistently identifies this alliance—the quality of the relationship between participant and therapist—as one of the strongest predictors of positive outcomes. Murphy et al. (2022) found that the therapeutic relationship quality predicted therapeutic outcomes over and above the intensity of the psychedelic experience itself. The molecule provides the opening. The relationship determines what can walk through it.

3. The dosing session. A single session lasting 6-8 hours, during which the psilocybin is administered and the participant is supported by two trained therapists throughout. This is the part most people think of when they hear “psilocybin therapy.” It’s also the part most often misunderstood. More on this below.

4. Integration sessions. Typically two to four meetings in the days and weeks following the dosing session. These sessions help the participant process, contextualize, and apply the insights and emotions that surfaced during the experience. Integration is where therapeutic change becomes sustainable—where a profound experience in an altered state translates into lasting shifts in perspective, behavior, and self-understanding in ordinary consciousness.

Without integration, even the most powerful psilocybin experience tends to fade. The initial weeks after a session often produce a glow—a sense of openness, clarity, and emotional richness that researchers call the “afterglow period.” Integration work capitalizes on this period of heightened plasticity to consolidate change. Skip it, and you’re more likely to end up with a remarkable memory than a transformed life.

What a Session Actually Looks Like

You wouldn’t know it was a medical procedure by looking at the room.

The treatment rooms at Johns Hopkins, Imperial College, NYU, and most Oregon service centers are designed to feel residential, not clinical. Comfortable couch or bed. Soft lighting. Art on the walls. Flowers, sometimes. The aesthetic is deliberate—clinical environments activate associations with illness, medical authority, and vulnerability that can shape the psychological landscape of the experience in counterproductive ways. A living room invites a different relationship with what’s happening than an exam room does.

The participant arrives having fasted lightly—eating lightly or not at all for a few hours before the session, to optimize absorption and minimize nausea. The therapists are present. There’s a brief check-in: how are you feeling, do you have questions, is your intention still what you discussed in preparation. The psilocybin is administered in a capsule—synthetic psilocybin in clinical trials, measured to the milligram.

Then the eyeshades go on. And the music starts.

The Eyeshades

The eyeshades serve a specific purpose. They redirect attention inward. With external visual input blocked, the psychedelic experience becomes more introspective, more emotionally focused, and more likely to produce the kind of deep personal insight that the therapeutic model depends on. Participants who keep their eyes open during psilocybin sessions tend to have more perceptual-exploratory experiences—fascinating, but less therapeutically targeted. The eyeshades aren’t mandatory. But the data supports their use for therapeutic outcomes, and every major research protocol includes them.

The Music

The music might be the most underappreciated element of the entire protocol.

Barrett et al. (2017) published the Johns Hopkins psilocybin therapy playlist and the rationale behind it. The playlist is carefully sequenced to guide the emotional arc of the session. It starts with ambient, grounding music during the onset period. As the effects build, the music intensifies—sweeping orchestral works, emotionally evocative classical pieces, sacred choral music. The peak of the session coincides with the most emotionally powerful music. As the effects wane, the playlist shifts to gentler, restorative pieces. The final hour features warm, integrative music that supports a sense of return.

The playlist is overwhelmingly instrumental. Lyrics anchor the mind in language and narrative; instrumental music allows the emotional content to remain open, personal, and fluid. Many participants later report that specific pieces of music became the vessel for their most significant experiences—a particular passage coinciding with a moment of emotional release, or a shift in the music corresponding to a shift in their inner landscape.

This isn’t background music. It’s a therapeutic instrument. The Hopkins team found that participants' experience of the music—how deeply it resonated, how fully they surrendered to it—was one of the strongest predictors of both mystical-type experience and long-term therapeutic benefit. The music doesn’t just accompany the therapy. In some sense, it is the therapy, working alongside the psilocybin to guide the participant through an emotional arc that neither the music nor the molecule could produce alone.

The Therapists' Role

Two therapists are present throughout the session. Their job is not to guide, interpret, or direct the experience. Their job is to hold space.

In practice, this means: sitting quietly. Being present. Offering physical reassurance if requested—a hand to hold, a blanket, a glass of water. Gently redirecting if the participant becomes stuck in a loop of anxiety or resistance, usually with a simple verbal cue: “Let go.” “Trust the process.” “You’re safe.” These interventions are minimal and rare. The therapeutic model is explicitly non-directive. The psilocybin and the participant’s own psyche generate the material. The therapists provide safety, containment, and the implicit permission that comes from knowing someone is there if you need them.

The participant typically spends most of the session lying down with eyeshades on, silent or occasionally speaking about what they’re experiencing. Some sessions involve tears—sometimes profound grief, sometimes overwhelming gratitude. Some involve extended periods of stillness. Some involve physical movement or changes in breathing. The therapists observe, support, and do not interfere.

After the peak effects have subsided—typically 4-5 hours in—the eyeshades come off. There’s a debrief conversation, usually brief and impressionistic. The detailed processing happens in the integration sessions that follow.

Conditions Being Treated

Psilocybin therapy is not a treatment for everything. The research, while extraordinary, is focused on specific conditions where the evidence is strong enough to justify clinical investment. Here’s where the data stands.

Depression

The most extensive evidence. Multiple large-scale trials have demonstrated rapid, substantial, and durable antidepressant effects.

Davis et al. (2021) at Johns Hopkins: 24 adults with major depressive disorder received two psilocybin sessions with therapeutic support. At four weeks, 71% showed clinically significant response (greater than 50% reduction in depression severity). Fifty-four percent were in full remission. A one-year follow-up found that 75% maintained response and 58% remained in remission—from two dosing sessions, without ongoing medication.

Carhart-Harris et al. (2021) at Imperial College London: head-to-head comparison with escitalopram (Lexapro) in 59 patients. Psilocybin matched the SSRI on the primary outcome and significantly outperformed it on every secondary measure—emotional responsiveness, social functioning, psychological well-being, and the capacity to experience pleasure. The SSRI blunted emotions. The psilocybin opened them.

COMPASS Pathways completed a large Phase 2b trial for treatment-resistant depression—patients who had failed at least two conventional antidepressant treatments. Results showed significant improvement at the highest dose tested, though the response was variable and not all participants benefited.

End-of-Life Anxiety and Depression

This is where the research first gained traction, and where some of the most moving data exists.

Griffiths et al. (2016) at Hopkins and Ross et al. (2016) at NYU published simultaneous landmark studies showing that a single high-dose psilocybin session produced rapid, substantial, and sustained reductions in anxiety and depression in patients with life-threatening cancer diagnoses. At six months, approximately 80% of participants in the Hopkins study showed clinically significant decreases in distressed mood. Most strikingly, participants didn’t just report less anxiety—they reported a fundamental change in their relationship to death. Terms like “acceptance,” “peace,” and “understanding” appeared repeatedly in qualitative interviews. Several participants described the psilocybin session as among the most meaningful experiences of their lives.

These studies were what first made mainstream medicine pay serious attention. When terminally ill patients report that a single session with a mushroom compound did more for their existential distress than months of conventional therapy, the field has to reckon with that.

Alcohol Use Disorder

Bogenschutz et al. (2022) published in JAMA Psychiatry the first randomized controlled trial of psilocybin for alcohol use disorder. Ninety-three participants received either psilocybin or diphenhydramine (active placebo) alongside psychotherapy. The psilocybin group showed an 83% reduction in heavy drinking days over the 32-week follow-up, compared to 51% for the placebo group. Percentage of days abstinent was significantly higher in the psilocybin condition.

The effect sizes were striking. Alcohol use disorder is notoriously difficult to treat—existing medications (naltrexone, acamprosate, disulfiram) have modest efficacy and poor adherence. A treatment that produces an 83% reduction in heavy drinking with two sessions and no ongoing medication regimen is, in the addiction medicine landscape, remarkable.

Smoking Cessation

Johnson et al. (2014) published a small pilot study at Hopkins that produced what may be the most eye-catching abstinence rates in the smoking cessation literature: 80% of participants were biologically confirmed abstinent at six months. For context, the best existing pharmacotherapy for smoking cessation—varenicline (Champix/Chantix)—achieves roughly 35% abstinence at six months. Nicotine patches run around 20%.

The study was small (15 participants) and uncontrolled, so the numbers should be interpreted cautiously. But a larger randomized trial is underway, and the pilot data was compelling enough to justify it.

Emerging Areas

Anorexia nervosa: Early-phase trials are investigating whether psilocybin therapy can address the rigid thought patterns and distorted self-perception characteristic of anorexia. The rationale is neurologically sound—anorexia involves hyperactive default mode network patterns that psilocybin is known to disrupt—but the clinical data is still preliminary.

OCD: Small pilot data suggests potential benefit for treatment-resistant obsessive-compulsive disorder, though larger trials are needed.

Cluster headaches: Anecdotal reports of psilocybin aborting cluster headache cycles are longstanding and consistent, and formal research is underway. This application doesn’t require the full therapeutic protocol—it appears to be a direct pharmacological effect.

Where It’s Available Now

Oregon, United States

Oregon’s Measure 109, passed in 2020, made the state the first US jurisdiction to legalize supervised psilocybin therapy. Licensed psilocybin service centers have been operating since 2023. The Oregon model doesn’t require a diagnosis—anyone over 21 can access psilocybin services through a licensed facilitator. The process involves a mandatory preparation session (minimum 2 hours), the dosing session itself (at a licensed facility, with a trained facilitator present throughout), and no required integration—though it’s strongly recommended.

Cost: $1,500-3,000+ per session, and this is the hard reality. Insurance doesn’t cover it. The cost reflects facility fees, facilitator time (an 8-hour session is a full working day for the facilitator), and the regulatory overhead of operating a licensed center. For many people, this price point places legal psilocybin therapy out of reach—a genuine equity problem that the Oregon model hasn’t solved and that advocates are working to address.

What to know: The Oregon facilitator model is not identical to the clinical research model. Facilitators receive training through approved programs, but the depth and approach vary. Some facilitators come from psychotherapy backgrounds; others don’t. The experience may differ significantly from the structured clinical protocol described above. Research the specific center and facilitator before committing.

Colorado, United States

Colorado passed Proposition 122 in 2022, decriminalizing psilocybin possession for personal use and directing the state to establish a regulated system for therapeutic psilocybin services. The regulatory framework is actively being developed. Licensed healing centers are expected to begin operating on a timeline that’s still being finalized. The Colorado model is expected to resemble Oregon’s in broad strokes but with some structural differences.

Canada

Canada offers several access pathways, each with different requirements:

Health Canada Special Access Program (SAP): Physicians can request access to psilocybin for patients with serious or life-threatening conditions when other treatments have failed or are unavailable. This pathway exists but is used conservatively—approval is not guaranteed, and the application process is substantial.

Section 56 exemptions: Health Canada can grant individual exemptions from the Controlled Drugs and Substances Act for medical or scientific purposes. Several patients with terminal diagnoses have received exemptions for psilocybin-assisted therapy. The exemption is case-by-case and typically requires advocacy.

Clinical trials: Multiple psilocybin trials are active in Canada, offering access to participants who meet specific enrollment criteria. ClinicalTrials.gov lists current studies.

Jamaica

Jamaica has no legislation prohibiting psilocybin. The compound was simply never scheduled. This legal gap has enabled a growing retreat industry, with centers offering supervised psilocybin experiences in various formats—from single-session therapeutic work to multi-day retreats incorporating group and individual sessions. Quality and approach vary enormously. Some centers employ licensed therapists and follow evidence-based protocols. Others are more informal. Due diligence is essential.

The Netherlands

Psilocybin-containing truffles (sclerotia) are legal in the Netherlands under a regulatory distinction from mushrooms (which were banned in 2008). A substantial retreat industry serves both Dutch residents and international visitors. Sessions typically involve preparation, a facilitated truffle experience, and integration support. The legal framework provides some consumer protection, but the industry is not medically regulated in the way clinical trials are. Amsterdam and other cities host multiple retreat centers.

Clinical Trials

For people who cannot afford legal services or don’t live in an access jurisdiction, clinical trials represent the most structured and highest-quality pathway to psilocybin therapy—and they’re free. The tradeoff is competitive enrollment, strict eligibility criteria, and the possibility of being randomized to a control group.

Active and recruiting trials can be searched at ClinicalTrials.gov using search terms like “psilocybin” filtered by condition, location, and recruitment status. As of this writing, trials are active across the US, Canada, UK, Europe, and Australia for conditions including depression, PTSD, alcohol use disorder, anorexia, and end-of-life distress.

Who Is Not a Candidate

Psilocybin therapy is not for everyone. The exclusion criteria exist because the risks for certain populations are real, not because researchers are being conservative for its own sake.

Psychotic disorders. Schizophrenia, schizoaffective disorder, and any condition involving psychotic features. Psilocybin can exacerbate psychotic symptoms and potentially trigger psychotic episodes. A personal history of psychosis is an absolute contraindication. A first-degree family history (parent, sibling) of psychotic disorders is typically an exclusion criterion in clinical trials, reflecting the elevated genetic risk.

Bipolar I disorder. Particularly with a history of manic or psychotic episodes. The serotonergic activation produced by psilocybin carries a risk of triggering manic episodes. Bipolar II, which involves hypomania rather than full mania, exists in a grayer area—some researchers are cautiously exploring it, but it’s not currently an established indication.

Lithium use. The combination of psilocybin and lithium has been associated with seizures in case reports. This is one of the few genuinely dangerous drug interactions in the psilocybin literature. Anyone taking lithium should not use psilocybin.

Certain cardiac conditions. Psilocybin produces modest increases in heart rate and blood pressure. For healthy individuals, this is clinically insignificant. For people with uncontrolled hypertension, severe cardiovascular disease, or conditions where transient blood pressure elevation could be dangerous, the risk-benefit calculation changes.

People on MAOIs. Monoamine oxidase inhibitors interact with serotonergic compounds and can produce serotonin syndrome—a potentially life-threatening condition. This includes both pharmaceutical MAOIs (phenelzine, tranylcypromine) and natural MAOIs found in some supplements and foods.

People in acute crisis. Active suicidal ideation, recent psychiatric hospitalization, or acute psychological destabilization are not appropriate states in which to undertake a powerful psychedelic experience. Stabilization first. Psilocybin therapy second.

DIY vs. Clinical: Why the Protocol Matters

“Just eat some mushrooms” is not psilocybin therapy. The distinction isn’t gatekeeping. It’s pharmacology and psychology.

The compound is the same. The experience can be profoundly different.

Clinical psilocybin therapy wraps the pharmacological event inside layers of support: screening ensures safety, preparation builds trust and intention, the controlled environment eliminates external stressors, trained therapists provide real-time support during vulnerable moments, and integration translates acute experience into lasting change. Each layer contributes to both safety and efficacy.

Self-administration removes most of those layers. No screening means no identification of contraindications. No preparation means less psychological readiness for challenging material. No controlled setting means environmental stressors can intrude. No trained support means difficult moments are navigated alone. No integration means insights fade rather than consolidate.

This isn’t hypothetical. The clinical data—the extraordinary response rates, the durable remission, the transformed relationship to death in terminally ill patients—was generated inside the full protocol. We don’t know what percentage of those outcomes are attributable to the psilocybin versus the therapy versus the music versus the relationship with the therapists versus the integration. What we know is that the whole package, together, produces results that no individual component has demonstrated alone.

Does self-administration help some people? Undoubtedly. The long history of traditional and informal psilocybin use includes countless reports of meaningful, positive, even life-changing experiences outside any clinical framework. People have been eating mushrooms for therapeutic and spiritual purposes for thousands of years without randomized controlled trials.

But the clinical model exists because it maximizes the probability of a positive outcome and minimizes the probability of harm. If you have the option, the structured path is the better bet. Not because the molecule needs a hospital. Because you might need the support.

The Future

The FDA’s breakthrough therapy designation for psilocybin—granted to both COMPASS Pathways and Usona Institute for treatment-resistant depression and major depressive disorder, respectively—is a regulatory signal that matters. Breakthrough designation doesn’t guarantee approval, but it accelerates the review process and indicates that the FDA considers the existing evidence substantial enough to warrant expedited development.

COMPASS Pathways is advancing through the Phase 3 trial process. Usona Institute is pursuing its own pathway. Multiple academic medical centers are building psychedelic research programs and training the next generation of therapists. The infrastructure for a post-prohibition therapeutic landscape is being assembled in real time.

What that landscape will look like remains uncertain. Will psilocybin therapy become a covered medical procedure? Will insurance companies pay for it? Will the cost come down enough to make it accessible to the people who most need it—not affluent wellness seekers, but the treatment-resistant, the terminally ill, the people who’ve tried everything else? Will the regulatory framework preserve the careful, relationship-intensive therapeutic model, or will economic pressure compress it into something faster, cheaper, and less effective?

These are open questions. The science is strong. The politics and economics are still being negotiated.

What isn’t in question is the underlying finding that set this entire movement in motion: a compound that grows naturally in pastures and forests, that human beings have been consuming for millennia, that was criminalized during a political panic and locked away for forty years, can—when administered carefully, in the right context, to the right people—produce therapeutic outcomes that the best existing pharmaceutical interventions cannot match.

The mushroom was always capable of this. The question was never whether it worked. The question was whether we’d build a system worthy of what it can do.